Gastrointestinal delivery of mRNA lipid nanoparticles selectively targets the pancreas.

ABSTRACT: Lipid nanoparticles (LNPs) administered parenterally often show poor localization to the gastrointestinal (GI) tract and pancreas. In addition, patients typically prefer orally administered drugs to those given intravenously. We therefore investigated whether GI delivery, achievable via device mediated microneedle injections applied to buccal, gastric, small intestinal, colonic, or rectal tissues, could simultaneously enhance LNP delivery to the GI and pancreas while avoiding intravenous administration. Using a combined approach of formulation optimization and GI delivery site screening, we found that cationic SM-102 LNPs delivered gastrically achieved 7-fold higher pancreas delivery in rodents than intravenous neutral SM-102 LNPs. With dose optimization, gastric LNPs achieved 6000-fold gr

SUBMITTER: Abbas AM 

PROVIDER: S-EPMC12458220 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature